• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Novartis Site Directory
Novartis logo : a global healthcare company
  • Our Work
    • Our Process
    • Clinical Trials
    • Clinical Pipeline
    • Product Portfolio
  • About Us
    • Who We Are
    • Our Business
    • Corporate Responsibility
    • Contact Us
    • AODA Compliant
    • Grants and Donations
    • AMA Compliant
    • Biome Canada, Montreal
  • Our Products
    • Pharmaceuticals
    • Health Care Professional
    • For Consumers
  • News
    • Media Releases
    • Media Contacts
    • Stories
    • FAQ
    • COVID-19 commitments
  • Careers
    • Careers Search
    • Working at Novartis
    • Employee Benefits
    • Student Programs
Search

News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

Advanced SearchBasic Search
2021

April

Media Release / Apr 29, 2021

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still’s disease

Read More
Media Release / Apr 28, 2021

Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)i

Read More
Media Release / Apr 13, 2021

Novartis in Canada named a Top 50 Best Workplace™ in the country

Read More

March

Media Release / Mar 23, 2021

Health Canada approves Kesimpta®, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis (RRMS)

Read More
Media Release / Mar 18, 2021

Novartis’ KISQALI® (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer

Read More
2020

June

Media Release / Jun 19, 2020

Statement from Novartis on AVXS-101 filing with Health Canada

Read More
Media Release / Jun 16, 2020

Long-term, relapse-free survival data for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery presented at ASCO20

Read More
Search Results Navigation
  • First page « first
  • Previous page ‹ previous
  • Page 1 of 2
  • Current page 2 of 2
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email

You are here

  1. Home ›
  2. News

Novartis Canada

  • Our Work
  • Notre travail
  • About Us
  • À propos de Novartis
  • Our Products
  • Nos Produits
  • News
  • Actualité
  • Careers
  • Carrière
  • Contact Us
  • Sites
  • Locations
  • Biome Canada, Montreal
  • Biome Canada, Montreal

Subscribe to Novartis

  • Twitter
  • Linkedin
  • Novartis Site Directory
© 2022 Novartis Pharmaceuticals Canada inc.
  • Terms of Use
  • Privacy Policy
  • Cookie Settings

This site is intended for an audience in Canada.